$2.060
-0.095 (-4.63%)At close
NAUT News
NAUT Events
Nautilus Biotechnology Files $300M Mixed Securities Shelf
Nautilus Biotechnology files $300M mixed securities shelf
Nautilus Partners with Baylor College for Early Access Program
Nautilus Biotechnology announced Baylor College of Medicine as the first customer of Nautilus' Iterative Mapping Early Access Program. Through a National Institutes of Health, or NIH, U01-funded study, Baylor will leverage Nautilus' novel single-molecule proteomics method to address a central challenge in cancer research - identifying aberrant protein isoforms that contribute to tumor growth, metastasis, immune evasion, and therapeutic resistance - while Nautilus expands early commercial access to its validated tau proteoforms assay. The study aims to develop a broadly accessible computational toolkit with improved detection of protein isoforms in conventional shotgun proteomics datasets. By pairing these computational approaches with full-length, isoform-resolved proteomic measurements generated on the Nautilus Voyager Platform, the project is intended to enable direct comparison of transcriptional and proteomic changes at unprecedented resolution.
Nautilus Biotechnology Appoints Amber Faust as VP of Sales
Nautilus Biotechnology announced the appointment of Amber Faust as Vice President of Sales. Faust joins Nautilus following the public debut of the Nautilus Voyager Platform.
Nautilus Biotechnology CEO Highlights Path to Commercialization by 2026
"In Q4, Nautilus maintained disciplined execution and delivered meaningful progress across our platform development, strategic collaborations, and early commercial engagement aligned with our path toward commercialization in late 2026," said Sujal Patel, CEO of Nautilus Biotechnology. "Our near-term focus remains on the successful expansion of our Early Access Program, beginning with Tau proteoforms and broadening over time, while continuing to advance our broadscale capabilities. These milestones are important steps toward enabling customers to experience the value of our technology and progressing toward full commercial availability."
Nautilus Biotechnology Launches Voyager Platform
Nautilus Biotechnology debuted the Voyager Platform, which is designed to power the Iterative Mapping of up to 10 billion intact proteins and proteoforms simultaneously in a single run. "We're excited to bring our vision of democratizing access to proteomics to fruition and share the Voyager Platform first with researchers seeking deeper insight into protein biology," said Parag Mallick, Ph.D., Co-Founder and Chief Scientist of Nautilus. "After years of intensive development, Voyager is designed to be a benchtop tool that can help advance biomarker discovery, diagnostics, and therapeutic innovation."
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.